| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013321 Used as ligands for opioid receptors, for therapy of neurological and gastrointestinal disorders |
| 01/31/2002 | US20020013311 Of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013274 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | DE19881732C1 New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | CA2416750A1 Compounds having mif antagonist activity |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416657A1 Fh-binding protein of streptococcus pneumoniae |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415606A1 Capsaicin receptor ligands |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2354236A1 Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| 01/30/2002 | EP1175504A1 Dna encoding the human vanilloid receptor vr1 |
| 01/30/2002 | EP1175490A2 Tyrosine kinase substrate (tks) proteins |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175445A1 Specific antibodies and antibody fragments for tgfbeta1 |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |
| 01/30/2002 | EP1175406A1 Imidazoline derivatives as alpha-1a adrenoceptor ligands |
| 01/30/2002 | EP1175402A1 Piperidine derivatives useful as ccr5 antagonists |
| 01/30/2002 | EP1175401A1 Piperazine derivatives useful as ccr5 antagonists |
| 01/30/2002 | EP1175383A1 Glucocorticoid receptor modulators |
| 01/30/2002 | EP1175246A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| 01/30/2002 | EP1175222A2 Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections |
| 01/30/2002 | EP1175216A2 Antimalarian agents for the treatment of asthma |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP0900225B1 Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
| 01/30/2002 | EP0863876B1 Quinoline derivatives containing a diol as leukotriene antagonists |
| 01/30/2002 | CN1333784A Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333781A Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333780A Benzylglycosylmmides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333778A Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333757A Quinazoline derivatives as medicaments |
| 01/30/2002 | CN1333754A Benzoheterocycles and their use as MEK inhibitors |
| 01/30/2002 | CN1333684A Use of 5HT3 receptor antagouists for the treatment of chronic fatigue syndrome |
| 01/30/2002 | CN1333682A Storable active substance concentrate with formoterol |
| 01/30/2002 | CN1333054A Medicine for relieving cough and asthma |
| 01/30/2002 | CN1333049A Anti common cold chewing gum |
| 01/30/2002 | CN1333043A Biyanshu capsule for treating rhinitis |
| 01/30/2002 | CN1333035A Medicinal tea for tracheitis and preparation process thereof |
| 01/30/2002 | CN1333020A Biochemical material composition for preventing and treating disease caused by smooth muscle cell contraction in human organ |
| 01/29/2002 | US6342601 Treating allograft rejection, rheumatoid arthritis |
| 01/29/2002 | US6342521 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 01/29/2002 | US6342510 Antiinflammatory agents and enzyme inhibitors |
| 01/29/2002 | US6342509 Antiasthmatics, antihistamines or bronchodialators |
| 01/29/2002 | US6342505 Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-β1 |
| 01/29/2002 | US6342502 Thieno[2,3-d]pyrimidine diones and their use in the treatment of reversible obstructive airways diseases |
| 01/29/2002 | CA2223769C Method of treatment for asthma |
| 01/29/2002 | CA2216789C Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers |
| 01/29/2002 | CA2145296C Benzenealkanoic acids for cardiovascular diseases |
| 01/24/2002 | WO2002006492A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 01/24/2002 | WO2002006453A2 Regulation of human desc1-like serine protease |
| 01/24/2002 | WO2002006316A2 Alpha-msh related compounds and methods of use |
| 01/24/2002 | WO2002006271A1 Pyrimidine derivatives |
| 01/24/2002 | WO2002006270A1 Novel 6-heteroarylphenanthridines |
| 01/24/2002 | WO2002006241A1 1, 2, 3, 5 -tetrahydrobenzo`c!azepin-4-one derivatives having muscarinic antagonist activity |
| 01/24/2002 | WO2002006236A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 01/24/2002 | WO2002006224A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | WO2002006223A1 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 01/24/2002 | WO2002006222A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 01/24/2002 | WO2002005847A1 Kubouchi's method of intramuscularly injecting mixture of drug with patient's blood and kubouchi's substances produced thereby |
| 01/24/2002 | WO2002005842A2 Preventing airway mucus production by administration of egf-r antagonists |
| 01/24/2002 | WO2002005830A2 Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof |
| 01/24/2002 | WO2002005814A1 Use of il-8 receptor antagonists in the treatment of virus infections |
| 01/24/2002 | WO2002005802A1 Method of fundamentally treating common cold |
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2002005784A1 A medicinal aerosol formulation |
| 01/24/2002 | WO2001058875A3 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives |
| 01/24/2002 | WO2001058869A3 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001039797A3 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus |
| 01/24/2002 | WO2001038305A3 Novel il-8 receptor antagonists |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001032910A3 27 human secreted proteins |
| 01/24/2002 | WO2001029000A3 Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| 01/24/2002 | WO2001022936A8 Topical suspension formulations containing ciprofloxacin and dexamethasone |
| 01/24/2002 | WO2001012819A3 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 01/24/2002 | WO2001008708A3 Enhanced delivery via serpin enzyme complex receptor ligands |
| 01/24/2002 | WO2001000655A3 Therapeutic peptides derived from subsequences of bpi |
| 01/24/2002 | WO2000071107A8 New pharmaceutical combinations for nos inhibitors |
| 01/24/2002 | US20020010351 Anticancer agents |
| 01/24/2002 | US20020010344 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| 01/24/2002 | US20020010343 Compounds having IgE affecting properties |
| 01/24/2002 | US20020010338 Phenyl-keto-imidazolidine thioamide derivatives |
| 01/24/2002 | US20020010318 Enzyme inhibitor; for use in treatment of lung defects, asthma, bronchitis, emphysema and respiratory system disorders |
| 01/24/2002 | US20020010315 Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. |
| 01/24/2002 | US20020010203 Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
| 01/24/2002 | US20020010197 Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity |
| 01/24/2002 | US20020010190 N-heterocyclic derivatives as NOS inhibitors |
| 01/24/2002 | US20020010189 For treatment of sexual disorders, male erectile dysfunction |
| 01/24/2002 | US20020010183 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 01/24/2002 | US20020010175 Diazepinoindoles for the treatment of chronic obstructive pulmonary disease |
| 01/24/2002 | US20020010174 1,4-diazepine-2-one derivatives as neurokinin antagonist |
| 01/24/2002 | US20020010170 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli |
| 01/24/2002 | US20020010168 Boswellic acid, salt or derivatives for preventing and/or combatting diseases caused by increased leucocytic elastase or plasmin activity in human or veterinary medincine, usedfor pulmonary emphysema, acute respiratory distress etc. |
| 01/24/2002 | US20020010146 Nitrosated and nitrosylated taxanes, compositions and methods of use |